Jefferies Seems to Have Lost Some Faith In Advaxis (NASDAQ:ADXS), Downgrades Stocks

June 13, 2018 - By Vivian Park

Advaxis, Inc. (NASDAQ:ADXS) Logo

Investors sentiment increased to 1.14 in 2018 Q1. Its up 0.02, from 1.12 in 2017Q4. It increased, as 10 investors sold Advaxis, Inc. shares while 18 reduced holdings. 9 funds opened positions while 23 raised stakes. 16.99 million shares or 11.99% more from 15.17 million shares in 2017Q4 were reported.

The California-based California State Teachers Retirement has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Geode Limited Com holds 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 285,323 shares. Barclays Public Limited Co holds 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 19,934 shares. Tower Research Capital Ltd Liability Company (Trc) invested in 10,718 shares. Pnc Financial Ser Gp holds 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS) for 24,000 shares. Wolverine Asset Ltd Liability Com reported 1,789 shares stake. Bank & Trust Of Montreal Can holds 2,259 shares. Rhumbline Advisers has invested 0% in Advaxis, Inc. (NASDAQ:ADXS). Dimensional Fund Advisors Lp stated it has 54,273 shares or 0% of all its holdings. Citadel Limited Liability Corp invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Raymond James Fin Serv stated it has 0% in Advaxis, Inc. (NASDAQ:ADXS). Renaissance Tech Limited has 0% invested in Advaxis, Inc. (NASDAQ:ADXS) for 992,394 shares. Victory Cap Management invested 0% of its portfolio in Advaxis, Inc. (NASDAQ:ADXS). Stonebridge Mgmt reported 0.02% stake. Bridgeway Cap Mngmt has 0% invested in Advaxis, Inc. (NASDAQ:ADXS).

Since December 29, 2017, it had 0 buys, and 3 insider sales for $20,259 activity. 32 shares were sold by LOMBARDO ANTHONY A, worth $94. Shares for $3,553 were sold by PETIT ROBERT.

Advaxis (NASDAQ:ADXS) Receives a Downgrade

New York-listed Advaxis (NASDAQ:ADXS), was lowered by investment analysts at Jefferies who lowered their rating on the $88.40M market cap firm to a “Hold”, but decided to stick with their PT of $2.0000 on ADXS shares.

Advaxis, Inc. (NASDAQ:ADXS) Ratings Coverage

Among 2 analysts covering Advaxis (NASDAQ:ADXS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis has $23.0 highest and $300 lowest target. $4’s average target is 138.10% above currents $1.68 stock price. Advaxis had 4 analyst reports since December 27, 2017 according to SRatingsIntel. Cantor Fitzgerald maintained Advaxis, Inc. (NASDAQ:ADXS) rating on Tuesday, March 13. Cantor Fitzgerald has “Overweight” rating and $5 target. On Wednesday, December 27 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by H.C. Wainwright on Friday, June 8 with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $6 target in Wednesday, March 14 report.

The stock decreased 8.70% or $0.16 during the last trading session, reaching $1.68. About 1.36 million shares traded or 113.43% up from the average. Advaxis, Inc. (NASDAQ:ADXS) has declined 79.31% since June 14, 2017 and is downtrending. It has underperformed by 91.88% the S&P500.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes technology based immunotherapies in the United States. The company has market cap of $88.40 million. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. It currently has negative earnings. The firm is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens.

More notable recent Advaxis, Inc. (NASDAQ:ADXS) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For June 13, 2018” on June 13, 2018, also Seekingalpha.com with their article: “Has A New Advaxis Awakened Out Of The Doldrums?” published on June 08, 2018, Benzinga.com published: “31 Stocks Moving In Wednesday’s Mid-Day Session” on June 13, 2018. More interesting news about Advaxis, Inc. (NASDAQ:ADXS) were released by: Seekingalpha.com and their article: “Advaxis Inc. (ADXS) CEO Ken Berlin on Q2 2018 Results – Earnings Call Transcript” published on June 07, 2018 as well as Benzinga.com‘s news article titled: “10 Biggest Price Target Changes For Wednesday” with publication date: June 13, 2018.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: